GC
TVTX icon

Globeflex Capital’s Travere Therapeutics TVTX Stock Holding History

Globeflex Capital’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-24,486
Closed -$500K – 522
2020
Q2 		$500K Buy
+24,486
New +$390K 0.13% 269
2016
Q1 		– Sell
-21,400
Closed -$413K – 496
2015
Q4 		$413K Hold
21,400
– – 0.11% 252
2015
Q3 		$434K Buy
+21,400
New +$634K 0.09% 298

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Globeflex Capital's TVTX Position: Q3 2020 in Review

Globeflex Capital sold out of Travere Therapeutics (TVTX) in Q3 2020, closing a stake of 24,486 shares — an estimated $500K sold.

Globeflex Capital first reported a position in TVTX in Q3 2015 and held it in 3 quarters. The position peaked at $500K in Q2 2020. 134 funds tracked by Wall St. Rank hold TVTX as of Q3 2020.

  • Globeflex Capital reported no remaining Travere Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Globeflex Capital sold 24,486 Travere Therapeutics shares in Q3 2020, an estimated $500K.
  • Globeflex Capital first reported a position in Travere Therapeutics in Q3 2015 and held it in 3 quarters.
  • Globeflex Capital's Travere Therapeutics position peaked at $500K in Q2 2020.
  • 134 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2020.

Based on Globeflex Capital's 13F filing for Q3 2020, filed 13 Nov 2020.